Exscientia

// about Exscientia

Exscientia designs small-molecule drug candidates with AI models, then runs its own automated labs to synthesize and test the top predictions, feeding real results back into the model to refine the next round. That closed loop between prediction and wet-lab testing is what it sells to partners, including several of the largest pharma companies, as a faster route from a disease target to a candidate ready for trials. It was among the first AI drug discovery companies to put a fully AI-designed molecule into human clinical trials.